Hanson Kristopher sold $73K of MPLT

Hanson Kristopher (General Counsel) sold 9,020 shares of MapLight Therapeutics, Inc. (MPLT) at $8.08 on 2026-10-15.

Original reporting
SEC EDGAR · Hanson Kristopher
Published Oct 16, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 16, 2026, 9:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MPLT
Bearish
medium confidence
Mentioned
$MPLT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MPLTBearishLow
01

Why it matters

Traders may briefly reassess sentiment around MPLT due to insider selling, but the filing does not provide new guidance, trial results, or corporate actions.

02

Market read

A disclosed insider sale can influence short-term sentiment, but it is unlikely to drive a sustained repricing without corroborating fundamental news.

03

What to watch

No 10b5-1 plan is cited, but the filing alone cannot distinguish discretionary selling from pre-planned arrangements or personal tax/expense needs.

Relevance 3/10Novelty 3/10Timing: filed after-hours on 2026-10-16, reflecting the 2026-10-15 sale

Background

This is an SEC Form 4 insider transaction disclosure for MapLight Therapeutics, Inc.

Company-level read

Ticker impact

$MPLTBearishMedium confidence
Context

MapLight Therapeutics insider Hanson Kristopher (General Counsel) sold 9,020 shares at $8.0800 on 2026-10-15 via an open-market sale.

Expected impact

Likely mild near-term sentiment drag as traders note insider selling, though impact should be limited without additional company-specific catalysts.

Evidence & confidence

Insider sales are common and this filing does not include new operational, financial, or regulatory developments; the transaction size is relatively small and there is no 10b5-1 plan disclosed.

Market effects

Minimal, as this is a single-company insider transaction with no sector-wide signal.

None.

None.

Counterpoint

The sale may be routine liquidity management and does not necessarily indicate negative fundamentals, especially without evidence of broader insider selling trends.

Key entities

  • MapLight Therapeutics, Inc.

    Company whose insider transaction is disclosed on Form 4.

  • Hanson Kristopher

    General Counsel who sold 9,020 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MPLTMed

MapLight Therapeutics 3Q 2026: EPS ($0.97) — 10-Q Summary

MapLight Therapeutics reported a wider net loss of $51.62M in 3Q 2026, up 75.5% YoY, due to increased R&D and clinical trial expenses. Diluted EPS was ($0.97). The company plans a Phase 3 schizophrenia trial and expects Alzheimer’s disease psychosis trial results in 2H 2027. Cash reserves of $463.4M are expected to last through 2028.

$MPLTHigh

MapLight Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

MapLight Therapeutics, Inc. (MPLT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 MapLight Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update Planning underway for ZEPHYR-2, the confirmatory Phase 3 trial of ML-007C-MA in schizophrenia, with topline results expected in the second half 2027 Enrollment ongoing in